Atsenokumarola

When ATH:
B01AA07

Characteristic.

Anticoagulant of indirect actions. White or white with blue polka crystalline powder;. Insoluble in water and slightly soluble in alcohol.

Pharmacological action.
Antykoahulyantnoe.

Application.

Prevention and treatment of thrombosis, tromboflebitov, thromboembolic complications of myocardial infarction, atrial fibrillation and other diseases; the prevention of thromboembolic complications in the postoperative period.

Contraindications.

Hypersensitivity, gyemorragichyeskii diatyez, gipoprotrombinemii, hypocoagulation state, kidney and / or liver failure, arterial hypertension, malignant neoplasms, diabeticheskaya retinopathy, physical exhaustion, гиповитаминоз K и C, erosive and ulcerative lesions of the gastrointestinal tract, perikardit, pregnancy, breastfeeding.

Restrictions apply.

Be wary appoint women of childbearing age (pregnancy should be ruled), elderly patients.

Side effects.

Angiostaxis, hemorrhages in the skin and mucous membranes-hematuria, gingivorragija, petechiae, post-traumatic hematoma, ground, metrorragija, gemartroz, hemorrhagic stroke; headache, nausea, vomiting, diarrhea; alopecia, skin necrosis, allergic reactions-fever, skin rashes; the syndrome is an increased risk of thrombosis.

Cooperation.

Effect reduce barbiturates atsenokumarola, increase-salicylates. Atsenokumarola increases the effect of oral hypoglycemic agents, toxic effect of phenytoin, ulcerogenic action of glucocorticoids.

Dosing and Administration.

Inside, at the same time. First day: Once 8-16 mg, further reduce the dose (Under the control of PTI). Maintenance dose (after reducing the amount of prothrombin index up 50%): 1-6 mg 1 once a day.

Precautions.

Treatment stop gradually atsenokumarola, reducing the dose and increasing the intervals between doses. During treatment requires monitoring of the general state of the patient and changes in blood coagulation.